203 related articles for article (PubMed ID: 31943701)
1. Cytolysin-positive Enterococcus faecalis is not increased in patients with non-alcoholic steatohepatitis.
Lang S; Demir M; Duan Y; Martin A; Schnabl B
Liver Int; 2020 Apr; 40(4):860-865. PubMed ID: 31943701
[TBL] [Abstract][Full Text] [Related]
2. Bacteriophage targeting of gut bacterium attenuates alcoholic liver disease.
Duan Y; Llorente C; Lang S; Brandl K; Chu H; Jiang L; White RC; Clarke TH; Nguyen K; Torralba M; Shao Y; Liu J; Hernandez-Morales A; Lessor L; Rahman IR; Miyamoto Y; Ly M; Gao B; Sun W; Kiesel R; Hutmacher F; Lee S; Ventura-Cots M; Bosques-Padilla F; Verna EC; Abraldes JG; Brown RS; Vargas V; Altamirano J; Caballería J; Shawcross DL; Ho SB; Louvet A; Lucey MR; Mathurin P; Garcia-Tsao G; Bataller R; Tu XM; Eckmann L; van der Donk WA; Young R; Lawley TD; Stärkel P; Pride D; Fouts DE; Schnabl B
Nature; 2019 Nov; 575(7783):505-511. PubMed ID: 31723265
[TBL] [Abstract][Full Text] [Related]
3. IgY antibodies against cytolysin reduce ethanol-induced liver disease in mice.
Cabré N; Hartmann P; Llorente C; Kouno T; Wang Y; Zeng S; Kim HY; Zhang X; Kisseleva T; Iyer S; Kudumala S; Schnabl B
Hepatology; 2023 Jul; 78(1):295-306. PubMed ID: 36811393
[TBL] [Abstract][Full Text] [Related]
4. Development of a Quantitative PCR Method for Detecting
Cabré N; Yang Y; Wang Y; Schnabl B
Methods Protoc; 2023 Nov; 6(6):. PubMed ID: 37987354
[TBL] [Abstract][Full Text] [Related]
5. Alcohol, microbiome, life style influence alcohol and non-alcoholic organ damage.
Neuman MG; French SW; Zakhari S; Malnick S; Seitz HK; Cohen LB; Salaspuro M; Voinea-Griffin A; Barasch A; Kirpich IA; Thomes PG; Schrum LW; Donohue TM; Kharbanda KK; Cruz M; Opris M
Exp Mol Pathol; 2017 Feb; 102(1):162-180. PubMed ID: 28077318
[TBL] [Abstract][Full Text] [Related]
6. Bacteriophage Prevents Alcoholic Liver Disease.
Çolakoğlu M; Xue J; Trajkovski M
Cell; 2020 Jan; 180(2):218-220. PubMed ID: 31978341
[TBL] [Abstract][Full Text] [Related]
7. Two-component regulator of Enterococcus faecalis cytolysin responds to quorum-sensing autoinduction.
Haas W; Shepard BD; Gilmore MS
Nature; 2002 Jan; 415(6867):84-7. PubMed ID: 11780122
[TBL] [Abstract][Full Text] [Related]
8. Fecal Microbiota in Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis: A Systematic Review.
Mohammadi Z; Poustchi H; Motamed-Gorji N; Eghtesad S; Hekmatdoost A; Saniee P; Merat S
Arch Iran Med; 2020 Jan; 23(1):44-52. PubMed ID: 31910634
[TBL] [Abstract][Full Text] [Related]
9. A novel means of self-protection, unrelated to toxin activation, confers immunity to the bactericidal effects of the Enterococcus faecalis cytolysin.
Coburn PS; Hancock LE; Booth MC; Gilmore MS
Infect Immun; 1999 Jul; 67(7):3339-47. PubMed ID: 10377111
[TBL] [Abstract][Full Text] [Related]
10. The Enterococcus faecalis cytolysin: a novel toxin active against eukaryotic and prokaryotic cells.
Coburn PS; Gilmore MS
Cell Microbiol; 2003 Oct; 5(10):661-9. PubMed ID: 12969372
[TBL] [Abstract][Full Text] [Related]
11. Review article: the gut microbiome as a therapeutic target in the pathogenesis and treatment of chronic liver disease.
Woodhouse CA; Patel VC; Singanayagam A; Shawcross DL
Aliment Pharmacol Ther; 2018 Jan; 47(2):192-202. PubMed ID: 29083037
[TBL] [Abstract][Full Text] [Related]
12. Interactions between the cecal microbiota and non-alcoholic steatohepatitis using laying hens as the model.
Hamid H; Zhang JY; Li WX; Liu C; Li ML; Zhao LH; Ji C; Ma QG
Poult Sci; 2019 Jun; 98(6):2509-2521. PubMed ID: 30690636
[TBL] [Abstract][Full Text] [Related]
13. Gut microbiota dysbiosis in patients with non-alcoholic fatty liver disease.
Shen F; Zheng RD; Sun XQ; Ding WJ; Wang XY; Fan JG
Hepatobiliary Pancreat Dis Int; 2017 Aug; 16(4):375-381. PubMed ID: 28823367
[TBL] [Abstract][Full Text] [Related]
14. Microbiota-Associated Therapy for Non-Alcoholic Steatohepatitis-Induced Liver Cancer: A Review.
Chen YH; Wu WK; Wu MS
Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32825440
[TBL] [Abstract][Full Text] [Related]
15. Alcohol, liver disease and the gut microbiota.
Bajaj JS
Nat Rev Gastroenterol Hepatol; 2019 Apr; 16(4):235-246. PubMed ID: 30643227
[TBL] [Abstract][Full Text] [Related]
16. Enterococcal cytolysin: activities and association with other virulence traits in a pathogenicity island.
Shankar N; Coburn P; Pillar C; Haas W; Gilmore M
Int J Med Microbiol; 2004 Apr; 293(7-8):609-18. PubMed ID: 15149038
[TBL] [Abstract][Full Text] [Related]
17. Targeting pathobionts for the treatment of alcohol-associated liver disease.
Lang S; Demir M; Schnabl B
Liver Int; 2021 Jan; 41(1):239-240. PubMed ID: 33159427
[No Abstract] [Full Text] [Related]
18. Microbiota and Fatty Liver Disease-the Known, the Unknown, and the Future.
Lang S; Schnabl B
Cell Host Microbe; 2020 Aug; 28(2):233-244. PubMed ID: 32791115
[TBL] [Abstract][Full Text] [Related]
19. Structure-Activity Relationships of the Enterococcal Cytolysin.
Rahman IR; Sanchez A; Tang W; van der Donk WA
ACS Infect Dis; 2021 Aug; 7(8):2445-2454. PubMed ID: 34265205
[TBL] [Abstract][Full Text] [Related]
20. Structure, function, and biology of the Enterococcus faecalis cytolysin.
Van Tyne D; Martin MJ; Gilmore MS
Toxins (Basel); 2013 Apr; 5(5):895-911. PubMed ID: 23628786
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
